Home
About Us
Development areas
Pipeline
Partnering
Events
Media
Contact
The company
Business strategy
Senior management
Board of directors
Investors
Parkinson's disease
Alzheimer's disease and cognitive disorders
Post-traumatic stress disorder
Drug dependency
Bipolar disorder
Restless legs syndrome
Anxiety
2007 press releases
2008 press releases
2009 press releases
2010 press releases
Features
Press releases
2 0 0 7
2 0 0 8
2 0 0 9
2 0 1 0
2009
Topic
13 May
Synosia Therapeutics Begins Phase I Trial of a New Generation Treatment for Cognitive Impairment
Synosia Therapeutics startet Phase-I-Studie einer neuartigen Therapie für Kognitive Störungen
10 March
Synosia Announces Second Agreement with Roche
Synosia Unterzeichnet Zweiten Vertrag mit Roche
07 January
Synosia Therapeutics Raises CHF32 Million in Series B Private Financing
Synosia Therapeutics nimmt CHF 32 Millionen in privater Finanzierungsrunde Serie B auf
Media Enquiries
Julie Walters
Tudor Reilly (Europe)
Tel: +44 (0) 1494 687860
Mobile: +44 (0) 775 3626967
Email:
julie.walters@tudor-reilly.com
Michele Parisi
Tudor Reilly (US)
Tel: +1 925 864 5028
Email:
michele.parisi@tudor-reilly.com
Download Company Brochure PDF
Get the fast facts on Synosia
Synosia's nepicastat is 'one to watch'
Finalist for Licensing Deal of the Year
EMAIL REGISTRATION
Sign up for regular updates
on Synosia.
Synosia Therapeutics adopts a privacy policy and will not disclose your email address or details to any third party.
Action you wish to take:
Subscribe
Unsubscribe
Your email address:
Copyright © 2009
Synosia Therapeutics.
All rights reserved.
Fill out the form below to send this web-page to a friend.
To:
E-mail address:
*
Separate multiple addresses with a comma (,)
Your Details:
Your name:
*
E-mail address:
*
Security image:
Please enter the numbers that appear here in the box below.
Security code:
*
* INFORMATION REQUIRED
THE DETAILS YOU PROVIDE ON THIS PAGE WILL NOT BE
USED TO SEND UNSOLICITED E-MAIL, AND WILL NOT BE
SOLD TO A 3RD PARTY.